Works matching IS 11738804 AND DT 2021 AND VI 35 AND IP 3

Results: 9

Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey.

Published in:

BioDrugs, 2021, v. 35, n. 3, p. 363, doi. 10.1007/s40259-021-00479-6

By:

Kolbe, Allison R.;
Kearsley, Aaron;
Merchant, Lubna;
Temkin, Eva;
Patel, Archita;
Xu, Jing;
Jessup, Amber

Publication type:

Article

A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study.

Published in:

BioDrugs, 2021, v. 35, n. 3, p. 325, doi. 10.1007/s40259-021-00482-x

By:

Marafini, Irene;
Stolfi, Carmine;
Troncone, Edoardo;
Lolli, Elisabetta;
Onali, Sara;
Paoluzi, Omero Alessandro;
Fantini, Massimo C.;
Biancone, Livia;
Calabrese, Emma;
Di Grazia, Antonio;
Monteleone, Ivan;
Lenti, Marco Vincenzo;
Di Sabatino, Antonio;
Monteleone, Giovanni

Publication type:

Article

Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Published in:

BioDrugs, 2021, v. 35, n. 3, p. 303, doi. 10.1007/s40259-021-00481-y

By:

Yu, Hannah J.;
Wykoff, Charles C.

Publication type:

Article

Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future.

Published in:

BioDrugs, 2021, v. 35, n. 3, p. 255, doi. 10.1007/s40259-021-00480-z

By:

Łobocka, Małgorzata;
Dąbrowska, Krystyna;
Górski, Andrzej

Publication type:

Article

Evolving Biosimilar Clinical Requirements: A Qualitative Interview Study with Industry Experts and European National Medicines Agency Regulators.

Published in:

BioDrugs, 2021, v. 35, n. 3, p. 351, doi. 10.1007/s40259-021-00478-7

By:

Druedahl, Louise C.;
Kälvemark Sporrong, Sofia;
van de Weert, Marco;
De Bruin, Marie Louise;
Hoogland, Hans;
Minssen, Timo;
Almarsdóttir, Anna Birna

Publication type:

Article

CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success.

Published in:

BioDrugs, 2021, v. 35, n. 3, p. 281, doi. 10.1007/s40259-021-00477-8

By:

Fiorenza, Salvatore;
Turtle, Cameron J.

Publication type:

Article

Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".

Published in:

2021

By:

Putzke, Joerg;
Haughie, Scott;
Zou, Kelly H.;
Ranganna, Gopinath M.

Publication type:

Letter

Author's Reply to Joerg Putzke et al. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".

Published in:

2021

By:

Qian, Jingjing;
Truong, Cong Bang;
Tanni, Kaniz Afroz

Publication type:

Letter

Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial.

Published in:

BioDrugs, 2021, v. 35, n. 3, p. 337, doi. 10.1007/s40259-021-00475-w

By:

Xu, Binghe;
Zhang, Qingyuan;
Sun, Tao;
Li, Wei;
Teng, Yue'e;
Hu, Xichun;
Bondarenko, Igor;
Adamchuk, Hryhoriy;
Zhang, Liangming;
Trukhin, Dmytro;
Wang, Shusen;
Zheng, Hong;
Tong, Zhongsheng;
Shparyk, Yaroslav;
Wang, Qingyu

Publication type:

Article